Peptide Vaccines for Infectious Disease
Peptide-Based COVID Vaccine Candidates
200+ trials
Over 200 clinical trials involving peptide vaccines for infectious diseases and cancer were active on ClinicalTrials.gov during 2023-2024.
Jahantigh et al., Therapeutic Advances in Infectious Disease, 2026
Jahantigh et al., Therapeutic Advances in Infectious Disease, 2026
View as imageMost vaccines work by exposing the immune system to a weakened or inactivated version of a pathogen. Peptide vaccines take a different approach. They use short, synthetic protein fragments, typically 8 to 30 amino acids long, that correspond to specific regions of a pathogen the immune system can recognize and attack. These fragments, called epitopes, are the minimum units needed to trigger an immune response without exposing the patient to any live or whole-pathogen material.
Peptide-based COVID vaccine candidates demonstrated this approach during the pandemic, with multiple candidates reaching clinical trials. But the strategy extends far beyond coronaviruses. Peptide vaccines are being developed or tested against influenza, HIV, HPV, CMV, malaria, tuberculosis, and hepatitis. Jahantigh et al. (2026) reviewed the field and documented over 200 active clinical trials involving peptide vaccines during 2023-2024 alone.[1]
Key Takeaways
- Peptide vaccines use synthetic protein fragments (epitopes) to activate B cells for antibody production and T cells for cellular immunity, without any live pathogen material (Jahantigh et al., 2026)
- CoVac-1, a multi-peptide SARS-CoV-2 vaccine using a TLR1/2 agonist adjuvant, induced T cell responses exceeding those from authorized mRNA vaccines in a phase I trial published in Nature (Heitmann et al., 2022)
- Self-assembling peptide nanofibers can act as both antigen carriers and immune adjuvants, eliminating the need for external adjuvants in some formulations (Rudra et al., 2010)
- Peptide-TLR7/8a conjugates that self-assemble into nanoparticles enhanced CD8+ T cell responses 15-fold compared to standard peptide vaccines in preclinical cancer and infection models (Lynn et al., 2020)
- A key limitation is HLA restriction: different individuals present different peptide epitopes, requiring multi-epitope designs to cover diverse populations
- Self-assembling peptide nanofibers displaying influenza hemagglutinin produced broader cross-strain antibody responses than soluble antigen alone (Roe et al., 2026)
The basic mechanism: epitopes and antigen presentation
Peptide vaccines work by hijacking the same molecular machinery the immune system uses to detect infections. When a virus or bacterium invades, the body's antigen-presenting cells (APCs), primarily dendritic cells, break pathogen proteins into short peptide fragments and display them on their surface using major histocompatibility complex (MHC) molecules. T cells scan these MHC-peptide complexes to determine whether the fragment is foreign and warrants an immune attack.
Peptide vaccines skip the infection step. They deliver pre-selected peptide epitopes directly to APCs. The process follows two parallel pathways:[1]
MHC class I presentation (CD8+ killer T cells). Short peptides (8-11 amino acids) bind MHC class I molecules on APCs, which then activate CD8+ cytotoxic T lymphocytes (CTLs). These CTLs can directly kill infected cells displaying the same peptide on their surface. This pathway is critical for clearing intracellular pathogens like viruses.
MHC class II presentation (CD4+ helper T cells). Longer peptides (13-25 amino acids) are processed and displayed on MHC class II molecules, activating CD4+ helper T cells. These helper cells coordinate the broader immune response: they enhance CTL function, stimulate B cells to produce antibodies, and generate immunological memory.
B cell epitopes (antibody production). Some peptide epitopes can directly stimulate B cells to produce antibodies that neutralize pathogens before they enter cells. Linear B cell epitopes from surface-exposed regions of viral proteins (like spike proteins) are common targets.
The strongest peptide vaccines include epitopes targeting all three pathways, combining CD8+ and CD4+ T cell epitopes with B cell epitopes in a single formulation.
Why use peptides instead of whole pathogens?
Traditional vaccine platforms (live-attenuated, inactivated, protein subunit) use whole or large portions of pathogens. Peptide vaccines offer specific advantages and carry specific trade-offs.
Safety. Peptide vaccines cannot cause infection. There is no risk of reversion to virulence (a concern with live-attenuated vaccines) or residual pathogenicity. This makes them suitable for immunocompromised patients who cannot safely receive live vaccines.[1]
Precision. By selecting only the most immunogenic epitopes, peptide vaccines avoid including pathogen components that might suppress immunity, cause autoimmune reactions, or trigger allergic responses. This is relevant for pathogens where whole-protein approaches have produced antibody-dependent enhancement (ADE) or other complications.
Manufacturing speed. Synthetic peptides can be produced by solid-phase peptide synthesis in days to weeks, without cell culture or fermentation. This matters during pandemic responses when speed is critical.
The trade-off: weak immunogenicity. Free peptides are small, soluble molecules that are rapidly degraded by proteases and cleared from the body before generating a strong immune response. This is the central challenge of peptide vaccine development. Without modifications or delivery systems, peptide vaccines produce weak and short-lived immunity compared to whole-pathogen vaccines.
Solving the immunogenicity problem
The field has developed multiple strategies to overcome the inherent weakness of peptide immunogens.
Adjuvants
Adjuvants are substances co-administered with peptide antigens to amplify the immune response. They work by activating pattern recognition receptors on innate immune cells, creating the "danger signals" that the immune system normally receives from actual infections.
Ko et al. (2025) encapsulated a TLR3 agonist in lipid nanoparticles and demonstrated potent T cell immunity against both cancer antigens and viral targets. The LNP formulation enhanced adjuvant delivery to lymph nodes and sustained immune activation over time.[2]
Yang et al. (2022) showed that heat-inactivated modified vaccinia virus Ankara (MVA) boosted both Th1 cellular and humoral immunity when used as a peptide vaccine adjuvant, outperforming conventional adjuvants like alum in generating CD8+ T cell responses.[3]
Zupin and Crovella (2022) proposed human defensins, naturally occurring antimicrobial peptides, as vaccine adjuvants. These innate immune molecules bridge the gap between innate and adaptive immunity and could serve as adjuvants that are already part of the human immune repertoire.[4]
Self-assembling peptide nanostructures
One of the most promising delivery approaches uses peptides that spontaneously organize into nanostructures. Rudra et al. (2010) demonstrated in PNAS that peptides engineered to self-assemble into nanofibers could act as their own immune adjuvants. The nanofiber architecture mimicked pathogen-associated molecular patterns, activating innate immune responses without any external adjuvant. Mice immunized with self-assembling peptide nanofibers carrying an ovalbumin epitope developed strong antibody responses comparable to those achieved with conventional adjuvants.[5]
Roe et al. (2026) extended this concept to influenza vaccines. Self-assembling peptide nanofibers displaying influenza hemagglutinin, combined with built-in adjuvant sequences, produced heterologous antibody responses broader than those from soluble antigen formulations. This cross-strain protection is relevant because influenza mutates rapidly and current seasonal vaccines often fail against drifted strains.[6]
Peptide-TLR conjugates
Lynn et al. (2020) published in Nature Biotechnology a strategy where peptide antigens are chemically conjugated to TLR-7/8 agonists. These conjugates self-assemble into uniform nanoparticles in aqueous solution. The approach solved two problems at once: it created a nanoparticle delivery vehicle and co-delivered the adjuvant and antigen to the same immune cell. CD8+ T cell responses were enhanced roughly 15-fold compared to admixed (unconjugated) peptide and adjuvant, and the approach worked across peptides with diverse physicochemical properties.[7]
Lipid-based delivery
Van Lysebetten et al. (2021) developed a lipid-polyglutamate nanoparticle platform designed specifically for peptide-based vaccines. The system encapsulated peptide antigens in a lipid shell that protected them from degradation and enhanced uptake by dendritic cells. The platform was designed to be modular: different peptide antigens could be loaded for different pathogens while using the same delivery vehicle.[8]
Clinical examples
CoVac-1: SARS-CoV-2 peptide vaccine
The most prominent recent example of a peptide vaccine for infectious disease is CoVac-1. Heitmann et al. (2022) published results in Nature from a phase I trial of this multi-peptide SARS-CoV-2 vaccine. CoVac-1 contained T cell epitopes derived from multiple viral proteins (not just the spike protein targeted by mRNA vaccines), combined with a TLR1/2 agonist adjuvant (XS15) in a Montanide emulsion.[9]
The results were striking: CoVac-1 induced multifunctional CD4+ and CD8+ T cell responses that surpassed those observed after authorized mRNA vaccines. By targeting epitopes across multiple viral proteins rather than just the spike, the vaccine aimed to produce broader immunity less susceptible to spike protein mutations. This directly addressed one of the core advantages of peptide vaccine design: the ability to select conserved epitopes that remain stable across viral variants.
Pancoronavirus designs
Yang et al. (2026) described a receptor binding domain-independent pancoronavirus vaccine assembled from conserved T and B cell epitopes shared across coronavirus family members. By avoiding reliance on the rapidly mutating receptor binding domain, this approach could theoretically provide protection against future coronavirus variants and novel coronaviruses not yet encountered.[10]
Shen et al. (2026) demonstrated that combining an exosomal T cell epitope vaccine with an antibody-inducing vaccine produced synergistic immune protection against SARS-CoV-2 in humanized mice. The combination activated both cellular and humoral arms of the immune system, a challenge that single-modality peptide vaccines often struggle to achieve alone.[11]
Influenza approaches
Beyond the nanofiber work by Roe et al. discussed above, Agamennone et al. (2022) reviewed antiviral peptide strategies against influenza, including vaccine approaches using conserved epitopes from the hemagglutinin stem and internal viral proteins like M2e and nucleoprotein. These conserved targets are less prone to the antigenic drift that forces annual reformulation of seasonal flu vaccines.[12]
HIV, HPV, and CMV
Peptide vaccine research extends across multiple infectious diseases. HIV peptide vaccines have been in development for decades, with the virus's extreme mutational capacity and immune evasion making it one of the most challenging targets. HPV peptide vaccines are exploring therapeutic approaches that go beyond the prophylactic coverage of existing vaccines like Gardasil, targeting the E6 and E7 oncoproteins that drive HPV-associated cancers. CMV peptide vaccines focus on protecting transplant recipients, a population where CMV reactivation causes serious morbidity.
Pharmacokinetic engineering
How long a peptide vaccine remains in the body, and where it goes, directly affects immune response quality. Mehta et al. (2020) published in Nature Biomedical Engineering that fusing peptide epitopes to albumin-binding carrier proteins dramatically improved vaccine immunogenicity. The fusion proteins accumulated in lymph nodes (where immune responses are initiated) and persisted longer than free peptides, which are rapidly cleared by the kidneys. This pharmacokinetic tuning approach increased T cell responses without changing the peptide sequence or adding traditional adjuvants.[13]
Key limitations
Peptide vaccines face several unresolved challenges that explain why they have not yet replaced conventional vaccine platforms for most infectious diseases.
HLA restriction. MHC molecules (called HLA in humans) are highly polymorphic. A peptide epitope that binds strongly to one HLA allele may not bind to another. This means a single-epitope peptide vaccine could be effective in some individuals but useless in others. Multi-epitope designs that include peptides restricted to different HLA alleles can address this, but increase vaccine complexity and manufacturing cost.
Conformational epitopes. B cells often recognize three-dimensional protein structures (conformational epitopes) rather than linear peptide sequences. Short synthetic peptides may not fold into the correct conformation to elicit neutralizing antibodies, limiting the humoral response. This is particularly relevant for envelope viruses where neutralizing antibodies target conformational epitopes on surface glycoproteins.
Immune memory duration. Whether peptide vaccine-induced immune memory persists as long as that from whole-pathogen vaccines or mRNA vaccines remains unclear for most infectious disease targets. The COVID-19 peptide trials are still generating long-term follow-up data.
Protease degradation. Natural L-amino acid peptides are susceptible to rapid degradation by proteases in blood and tissues. D-amino acid substitutions, cyclization, and nanoparticle encapsulation can improve stability, but add manufacturing complexity.
Understanding how peptide vaccines are designed, from epitope prediction through formulation, is essential context for evaluating any specific vaccine candidate.
The Bottom Line
Peptide vaccines for infectious disease work by delivering synthetic protein fragments that activate T cells and B cells through MHC-mediated antigen presentation. Their safety, precision, and manufacturing speed are genuine advantages over whole-pathogen platforms. The central challenge, weak immunogenicity of free peptides, is being addressed through adjuvant co-delivery, self-assembling nanostructures, TLR conjugation, and pharmacokinetic engineering. Clinical data from CoVac-1 and ongoing coronavirus, influenza, HIV, and HPV trials demonstrate that these approaches can produce immune responses matching or exceeding conventional vaccines, though long-term efficacy data for most targets is still accumulating.